Plasma Fractionation Market Report Scope & Overview:

The Plasma Fractionation Market was valued at USD 38.50 Billion in 2025 and is expected to reach USD 85.93 Billion by 2035, growing at a CAGR of 8.36% from 2026 to 2035.

Plasma fractionation exists to pull life-saving proteins, immunoglobulins, albumin, and coagulation factors chief among them, out of donated human plasma, and demand for those therapies keeps climbing as immune deficiency, autoimmune disease, and bleeding disorders become more widely diagnosed. Nervous system disorders currently account for the largest share of plasma-derived therapy use, followed by musculoskeletal and immune-mediated conditions, and that clinical demand keeps pushing manufacturers to expand both plasma collection capacity and fractionation plant output simultaneously. Advances in chromatography, depth filtration, and viral inactivation technology are improving both the purity and safety of finished plasma products, and that steady technical progress, paired with an expanding global network of plasma collection centers, continues to underpin growth across the industry.

Octapharma unveiled a major expansion at its Vienna plasma fractionation plant in February 2025, a USD 200 million project completed in just 15 months that boosted production area by more than two-thirds and created 160 new jobs, while Takeda announced in June 2024 a major expansion of plasma-derived therapy manufacturing capacity at its Los Angeles plant, the company's largest plasma fractionation site.

Market Size and Forecast

• Market Size in 2026E: USD 41.72 Billion
• Market Size by 2035: USD 85.93 Billion
• CAGR: 8.36% from 2026 to 2035
• Fastest Growing Region: Asia Pacific
• Largest Region: North America

Plasma Fractionation Market Trends

• Rising prevalence of immunodeficiency, hemophilia, and chronic diseases is driving the plasma fractionation market.
• Growing demand for immunoglobulins, clotting factors, and albumin is boosting market growth.
• Expansion of blood collection centers and plasma donation programs is increasing raw material availability.
• Advancements in fractionation technologies and purification processes are enhancing safety and yield.
• Increasing adoption of recombinant and plasma-derived therapies is widening application scope.

The U.S. Plasma Fractionation Market Outlook

The U.S. Plasma Fractionation Market was valued at approximately USD 15.13 Billion in 2025 and is expected to reach approximately USD 32.69 Billion by 2035, growing at a CAGR of approximately 8.01%.

North American market growth in plasma fractionation in the United States is led by its extensive system of plasma donation centers, manufacturing capabilities and high concentration of the industry’s key players. Favorable regulatory environment and increased demand for plasma derivatives will keep the position of the leading region intact, and possession of fractionation facilities by firms such as Takeda, CSL Behring and Grifols will maintain the advanced state of American plasma supply chain systems.

Takeda announced in June 2024 a major expansion of its plasma-derived therapy manufacturing capacity at its Los Angeles plant, the company's largest plasma fractionation site globally, reinforcing its commitment to meeting rising domestic and international demand for plasma-derived therapies.

Plasma Fractionation Market Segment Analysis

• By Products, the immunoglobulins segment dominated the plasma fractionation market with a 64.10% share in 2025, while the albumin segment is the fastest growing.
• By Method, the chromatography segment dominated the plasma fractionation market with a 35.6% share in 2025, while the centrifugation segment is the fastest growing.
• By Application, the neurology segment dominated the plasma fractionation market with a 29.8% share in 2025, while the oncology segment is the fastest growing.
• By End-Use, the hospitals & clinics segment dominated the plasma fractionation market with a 54.11% share in 2025, while the clinical research segment is the fastest growing.

By Products, immunoglobulins dominates the market, albumin segment expected to grow fastest

Immunoglobulins dominated the products segment in 2025, at 64.10%, driven by the growing incidence of immunodeficiency disorders, autoimmune diseases, and neurological conditions that respond well to immunoglobulin therapy. These products are used across many healthcare settings to manage conditions including primary immunodeficiency and chronic inflammatory demyelinating polyneuropathy, and that broad clinical utility keeps immunoglobulins firmly at the top of the product mix.

The albumin product type is projected to witness the highest growth rate in terms of market share, owing to its increasing applications in critical care, liver disease treatment, and surgery. The increasing awareness about the usage of albumin in fluid replacement therapy, shock therapy, and burn care, as a result of increasing accessibility to healthcare and declining costs of treatments in emerging nations, is expected to fuel the demand for albumin.

By Method, chromatography dominates the market, centrifugation segment expected to grow fastest

Chromatography held the largest method share in 2025, at 35.6%, since it achieves higher purity and selectivity separating plasma proteins than most other techniques available. Ion-exchange, affinity, and size-exclusion chromatography can all be applied to isolate specific plasma proteins, immunoglobulins, albumin, and coagulation factors among them, and that flexibility across multiple separation approaches keeps chromatography the preferred method across most large-scale fractionation facilities worldwide.

Centrifugation is expected to grow fastest among methods, driven by increasing use in early-stage plasma processing and smaller-scale or decentralized fractionation systems. Centrifugation provides an economic and effective method for separating plasma fractions using density differences, which makes it appropriate for current market requirements and for new plasma fractionation plants that are not ready yet for expensive chromatographic facilities.

By Application, neurology dominates the market, oncology segment expected to grow fastest

Neurology dominated the application segment in 2025, at 29.8%, driven by widespread use of immunoglobulins against neurological diseases including chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, and multifocal motor neuropathy. These disorders typically require prolonged immunoglobulin treatment, generating steady, recurring demand that keeps neurology firmly at the top of the broader application mix.

The segment of oncology will record the highest growth due to an increase in the utilization of plasma-based products for both research and clinical purposes in the cancer therapy and supportive treatment. Albumin-based chemotherapy agents like nab-paclitaxel rely on the use of plasma protein as the carrier for drug delivery, while immunoglobulin is being used to treat immunological challenges in oncology, thus promoting its fast growth in this industry.

By End-Use, hospitals & clinics dominates the market, clinical research segment expected to grow fastest

Hospitals and clinics dominated the end-use segment in 2025, at 54.11%, given their role delivering plasma-derived therapies intravenously in both acute and chronic care settings. These facilities are the first line of care for patients needing immunoglobulins for immunodeficiencies, albumin for critical care, and coagulation factors for bleeding disorders including hemophilia, keeping this end-use category firmly in the lead.

The clinical application of plasma-derived product is forecasted to witness the fastest growth amongst all end-users as it involves constant research and development efforts for broadening the indications for such plasma-derived products. Increased investments in trials for new indications and formulation combinations, in addition to the search for new applications of plasma proteins in areas such as oncology and rare genetic diseases, will fuel demand in this sector.

Regional Analysis

North America Plasma Fractionation Market Insights

North America dominated the plasma fractionation market in 2025, holding a 51.62% share, driven by well-established healthcare infrastructure, strong awareness of plasma-derived therapies, and dominance from key players including CSL Behring, Grifols, and Takeda. A well-developed network of plasma collection centers, particularly across the U.S., ensures a stable, large supply of source plasma, and that supply security keeps the region's manufacturers well positioned relative to competitors elsewhere in the world.

The United States accounts for roughly 76% of regional revenue, and favorable reimbursement policy, early adoption of advanced fractionation technology, and a large patient population dealing with immunological and bleeding disorders all continue to reinforce that lead. Canada contributes a smaller but steadily growing share as its own plasma collection infrastructure continues to expand, keeping North America firmly ahead of every other region in this market.

Europe Plasma Fractionation Market Insights

Europe's plasma fractionation market is expanding due to the scale of the region's biopharmaceutical infrastructure, an accommodating regulatory environment, and rising demand for plasma-derived therapies. An efficient hospital delivery network across the continent supports rapid uptake of biologic treatments for immunological, hematological, and neurological disease, and regional production capacity is being further bolstered by ongoing investment in plasma collection, processing, and R&D activity.

Germany is the leading market, contributing to about 27% of the European sales, thanks to Germany’s well-established biopharmaceutical production facilities and highly developed hospital industry. Meanwhile, France, the UK and Italy are also showing trends that are relatively similar because of the ongoing investments into the facilities in Europe for collecting and processing of plasma.

Asia Pacific Plasma Fractionation Market Insights

Asia Pacific is expanding at the fastest rate, with a projected CAGR of approximately 8.9% during the forecast period (2026-2035), driven by growing healthcare investment, rising diagnosis rates for rare and chronic diseases, and improving access to next-generation plasma-derived therapies. Rapid expansion of plasma collection and processing infrastructure across China, India, and Japan, supported by government initiatives and local manufacturing incentives, continues to accelerate regional market growth.

China leads regional demand, accounting for roughly 35% of Asia Pacific revenue, supported by increasing awareness of plasma-derived products and rising demand for immunoglobulins and albumin among the country's growing geriatric population. India and Japan are contributing meaningfully to regional growth as well, and that broad-based expansion across the region's largest healthcare systems is expected to keep Asia Pacific's growth rate well ahead of the global average.

MEA & Latin America Plasma Fractionation Market Insights

The plasma fractionation market across the Middle East & Africa and Latin America is seeing modest growth, largely driven by the gradual development of healthcare infrastructure and rising awareness of plasma-derived therapy benefits. Plasma networks across both regions remain relatively nascent, though several countries have opened new collection centers while working to maximize the potential of existing ones, with Saudi Arabia accounting for roughly 28% of MEA revenue.

Latin America is also going by a similar trend where Brazil generates approximately 44% of the revenue from the region owing to the development of its health care structure. Cooperation with manufacturers on a global scale and regulators who try to harmonize the process of approving plasma products help facilitate the growth of the sector.

Market Dynamics

Growth Drivers: Expanding plasma collection and fractionation capacity

As plasma-derived therapies have gained popularity, global demand has grown steadily, and major players including CSL Behring, Takeda, Octapharma, and Grifols have directed substantial capital toward expanding both plasma donation infrastructure and fractionation plant capacity. Organizations are simultaneously establishing new plasma donation centers and expanding existing fractionation plants to boost output, with Takeda's expansion of its Los Angeles facility, its largest fractionation site globally, illustrating the scale of investment currently flowing into this category to meet rising worldwide demand.

Technology development in terms of fractionation processes continues to boost the ability to expand even further. The latest methods used today include chromatography, depth filtration, and new viral inactivation techniques. They help in obtaining higher yields, purity, and safety of the produced product, which contributes to the improved process of isolating valuable plasma proteins. In March 2025, Octapharma became the first and only fractionator of the UK's Plasma-for-Medicines programme employing UK non-remunerated plasma in nearly three decades. This event is a good example of automation and modern viral inactivation technology influencing plasma supply chains.

Restraints: Stringent regulatory requirements across major markets

Plasma derived therapies are delicate biological materials posing the risk of infection from blood borne pathogens; hence, the governing bodies such as the FDA, EMA, and PMDA of Japan require high levels of safety, quality, and efficacy in all steps of fractionation and even in the end product. It is necessary for the companies manufacturing these drugs to meet these criteria through clinical studies, virus inactivation verification, screening of donors and tracing of batches.

These rigorous compliance measures can lengthen product development cycles, increase production costs, and require numerous audits and facility inspections before a product reaches market. Regulatory differences between regions further complicate international approvals and distribution logistics, and manufacturers operating across multiple jurisdictions must navigate a genuinely fragmented regulatory landscape that adds both time and cost to bringing new plasma-derived therapies to patients.

Opportunities: Expanding therapeutic indications and emerging market access

Continued research into new therapeutic applications for plasma-derived products is opening genuine opportunity across oncology, rare genetic diseases, and other emerging indications well beyond the traditional immunology and hematology use cases. Academic institutions, biotech firms, and pharmaceutical companies are all investing in clinical trials that could meaningfully expand the addressable patient population for plasma-derived therapies over the coming decade.

Growing plasma collection infrastructure across emerging markets in Asia Pacific, Latin America, and the Middle East is opening further opportunity for manufacturers positioned to establish early, durable supply relationships in these regions. As local manufacturing incentives and government-backed healthcare investment continue expanding plasma collection capacity outside the traditional North American and European strongholds, that structural shift is expected to keep widening the addressable market for plasma fractionation companies through 2035.

Recent Developments:

• 2025: Octapharma unveiled a major expansion at its Vienna plasma fractionation plant, a USD 200 million project completed in 15 months that boosted production area by more than two-thirds and created 160 new jobs.
• 2025: Octapharma became the only fractionator of the UK's Plasma-for-Medicines programme using UK-sourced, non-paid plasma for the first time in nearly three decades, integrating automated plasmapheresis with state-of-the-art viral inactivation technology.
• 2024: Takeda announced a major expansion of plasma-derived therapy manufacturing capacity at its Los Angeles plant, the company's largest plasma fractionation site, to meet rising global demand.
• 2023: CSL Behring inaugurated its Phoenix base fractionation plant in Marburg, Germany, following a five-year, USD 470 million investment, significantly increasing plasma processing capacity with new automation technology.

Plasma Fractionation Market key players are:

• CSL Behring
• Grifols, S.A.
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Kedrion Biopharma Inc.
• Bio Products Laboratory Ltd. (BPL)
• Sanquin Plasma Products B.V.
• LFB S.A.
• GC Biopharma Corp.
• Biotest AG
• Shanghai RAAS Blood Products Co., Ltd.
• Hualan Biological Engineering Inc.
• ADMA Biologics, Inc.
• Kamada Ltd.
• Emergent BioSolutions Inc.
• Intas Pharmaceuticals Ltd.
• China Biologic Products Holdings, Inc.
• SK Plasma Co., Ltd.
• Bharat Serums and Vaccines Limited (BSV)
• Haemonetics Corporation

Plasma Fractionation Market Report Scope :